Novilytic Secures Two Strategic Patents for its Proteometer Platform
https://www.novilytic.com/post/novilytic-secures-two-strategic-patents-for-its-proteometer-platform
Novilytic named a Finalist in BioTools Innvator's 2025 Competition
https://www.novilytic.com/post/novilytic-named-a-finalist-in-biotools-innovator-s-2025-competition

Novilytic is a company that helps upstream scientists in pharma and biopharma rapidly quantify mAb titer, aggregates, and charge variants directly from clarified fermentation broth. Their patented Proteometer technology eliminates the need for Protein A sample preparation, delivering actionable quality data in under 10 minutes. The platform simplifies workflows, reduces variability, and enables real-time process decisions. Novilytic's technology was developed by experts in analytical chemistry, and they offer a range of kits that analyze titer, aggregate, and charge variants of proteins containing a human Fc region.

Novilytic helps upstream scientists in pharma and biopharma rapidly quantify mAb titer, aggregates, and charge variants directly from clarified fermentation broth. Our patented Proteometer® technology eliminates the need for Protein A sample preparation, delivering actionable quality data in under 10 minutes. The platform simplifies workflows, reduces variability, and enables real-time process decisions

Inspired by the saying “canary in the coal mine,” Novilytic is “The Canary in the Fermentor,” delivering near-real-time protein quality insights that help upstream scientists detect issues early and move quickly to the next sample.

Novilytic's Proteometer simplifies biopharmaceutical analytics. Specifically, current analytical testing used in R&D relies on dated technology that requires multiple personnel, dozens of consumables, and five to six expensive instruments to obtain critical data.
It provides the same answers utilizing just one person, their existing instrument, and one Proteometer consumable kit.
The Proteometer platform comprises three kits that analyze titer, aggregate, and charge variants of proteins containing a human Fc region, such as mAbs and multi-specifics.
It is LC-agnostic and eliminates the need for Protein A purification and method development, enabling rapid, automated analysis.
The technology was developed by some of the brightest minds in analytical chemistry and spearheaded by Dr. Fred Regnier, formerly with Purdue University. We are fortunate to have a team of world-class chemists and business professionals who will continue to develop and promote Novilytic's cutting-edge innovations.